Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hepatitis B immunoglobulin in chronic hepatitis B with hepatocellular carcinoma
2020-003114-12Phase 4Terminated
- Sponsor
- Medical University of Graz
- Start
- Nov 2022
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of hepatitis B immune globulin in Chronic Hepatitis B (CHB) and hepatocellular carcinoma (HCC), sponsored by Medical University of Graz. Primary endpoint: HBsAg change from baseline to week 6. Started Nov 2022; status: terminated.
02
Drugs
hepatitis B immune globulin
03
Conditions
Chronic Hepatitis B (CHB)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2020-003114-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003114-12.